Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Donna Powell

Gastroenterology Tampa, FL Doctor of Osteopathy

NPI 1740459676 CMS profile 306541

5016 W Cypress St Ste 200, Tampa, FL 33607

Open in the dashboard

General payments

$11,976

563 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Donna Powell of Tampa, FL is reported in the CMS Open Payments database as having received $11,976 across 563 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,177 131
2024 General $2,368 107
2023 General $2,229 126
2022 General $1,922 65
2021 General $1,056 62
2020 General $727 40
2019 General $497 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Donna Powell
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Donna Powell were reported at $3,177. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Donna Powell Gastroenterology median Middle half National median
2019 $497 $417 $126–$1,100 $163
2020 $727 $224 $74–$624 $114
2021 $1,056 $352 $106–$1,054 $132
2022 $1,922 $448 $129–$1,270 $149
2023 $2,229 $533 $150–$1,390 $160
2024 $2,368 $605 $160–$1,606 $164
2025 $3,177 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,112 181 payments
  2. Janssen Biotech, Inc. $1,302 37 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,239 76 payments
  4. QOL Medical, LLC $816 24 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $734 40 payments
  6. Pfizer Inc. $569 25 payments
  7. Genzyme Corporation $535 20 payments
  8. Celgene Corporation $502 32 payments
  9. Regeneron Healthcare Solutions, Inc. $324 14 payments
  10. Madrigal Pharmaceuticals $308 8 payments
  11. Other $2,535 106 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,300 558 payments
  2. Consulting Fee $600 1 payment
  3. Education $76 4 payments
Products named General payments · program years 2019–2025
  1. CREON $1,301 84 payments
  2. STELARA $1,238 33 payments
  3. LINZESS $1,194 69 payments
  4. XIFAXAN $1,019 55 payments
  5. RINVOQ $837 57 payments
  6. Sucraid $570 16 payments
  7. SKYRIZI $556 35 payments
  8. ZEPOSIA $547 31 payments
  9. DUPIXENT $525 19 payments
  10. XELJANZ $475 24 payments
  11. Other $7,015 335 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

476

Median for Gastroenterology: 569

Drug cost

$223,578

Median for Gastroenterology: $104,976

Branded share of claims

25.4%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rinvoq Upadacitinib Brand 11 $82,345
Xifaxan Rifaximin Brand 15 $52,228
Creon Lipase/Protease/Amylase Brand 11 $48,767
Linzess Linaclotide Brand 24 $23,199
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 27 $4,531
Dexlansoprazole Dr Dexlansoprazole Brand 16 $4,520
Mesalamine Generic 17 $2,929
Omeprazole Generic 125 $1,458
Sucralfate Generic 11 $893
Famotidine Generic 84 $828

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$46,167

Medicare's payments for the services billed

Medicare patients

217

Average age 71

Services billed

563

174 women, 43 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 52%
Ischemic heart disease 32%
Depression 24%
Chronic kidney disease 21%
Osteoporosis 21%
Cancer 20%
Diabetes 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Sucraid
  • QOL Medical, LLC $354
$354 — —
SKYRIZI
  • AbbVie, Inc. $188
$188 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $100
  • GENZYME CORPORATION $80
$180 — —
RINVOQ
  • AbbVie, Inc. $171
$171 11 —
OMVOH
  • Lilly USA, LLC $141
$141 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

563 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record